Table 1 Baseline characteristics
From: High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma
Total (N =48) | Patient (N) | |
|---|---|---|
Age (Median/Range) | 59.3 (39.3-81.6) years | |
Sex (Male : Female) | 36 : 12 | |
Location | ||
  Parotid gland | 38 | |
  Submandibular gland | 10 | |
Stage | ||
  I | 4 | |
  II | 17 | |
  III | 6 | |
  IV | 21 | |
Treatment | ||
  Operation | 3 | |
  Operation + RT | 25 | |
|  | Radiation dose (Median/Range) | 5400°CGy (4000-6300°CGy) |
  Operation + CCRT | 14 | |
|  | Radiation dose (Median/Range) | 5940°CGy (5400-6000°CGy) |
| Â | Chemotherapy regimen | Â |
|  |   Cisplatin | 1 |
|  |   DP | 5 |
|  |   FP | 2 |
|  |   CAP | 4 |
|  |   Unknown | 2 |
  CCRT | 1 (Genexol/cisplatin) | |
  Palliative chemotherapy | 2 (CAP, XP) | |
  Palliative radiotherapy | 4 | |
Treatment response | ||
  No evidence disease | 23 | |
  Stable disease | 1 | |
  Recur or Progression | 19/5 | |
Recurrence sites | Total (N =19) | |
  Locoregional recurrence | 8 | |
  Lung | 6 | |
  Bone | 4 | |
  Liver | 2 | |
RFS (Median) | 29.1 months | |
OS (Median) | 76.2 months | |